U.S. Vaccine Market, By Product Type (Human Vaccine (Pediatric Vaccines, Adult & Adolescent Vaccines, Other Human Vaccines), Animal Vaccine (Livestock Vaccines, Companion Animal Vaccines, Other Animal Vaccines)), By End User (Hospitals, Clinics Vaccination, Centers)

Published In : Jul 2023

Code : CMI4011

Pages :176

Formats :

Excel and PDF

Industry : Biotechnology

Market News

U.S. Vaccine Market: Key Developments

In April 2022, Cadila Pharmaceuticals an multinational pharmaceutical company based in India, launched the world’s first three-dose anti-rabies vaccine. Its recombinant nano particle-based rabies G protein vaccine.

In September 2021, Serum Institute of India Pvt. Ltd Pharmaceutical company in India had started supplying Inactivated Polio Vaccine (IPV) to the Union government for the Universal Immunization Programme. Union health ministry had placed a purchase order with the Serum Institute of India for 54 lakh doses of IPV vaccine.

In June 2022, Bharat Biotech ltd. is a biotechnology company, introduced a new variant of INDIRAB is prepared using the strain obtained from the Centers for Disease Control and Prevention, USA. A cell culture-derived vaccine, it is produced in Vero Cells, inactivated and chromatographically purified.

In 2021, GlaxoSmithKline plc announced that they submitted a Biologics License Application (BLA) to the USFDA for its experimental vaccination PRIORIX. Over 100 nations have recently granted licenses for the vaccine, initially registered in Germany.

In 2020, GlaxoSmithKline plc and Medicago Inc., two of Mitsubishi Tanabe Pharma Corporation's subsidiary companies, announced their collaboration. They established a partnership to create a plant-based virus-like particle (VLP) vaccine for COVID-19.